R. Touhey Myer

Charles E. Lipsey

Mark J. Feldstein

Cora R. Holt

Michael P. Kelly

Daniel M. Silver

Benjamin A. Smyth

Jill K. MacAlpine

Ryan P. O'Quinn

Maximilienne Giannelli

Second ANDA clash erupts: AstraZeneca sues InvaGen over its generic BRILINTA®, targeting crystalline form patents for the blockbuster cardiovascular drug.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Astrazeneca LP

Astrazeneca Uk Ltd

Astrazeneca Pharmaceuticals LP

Astrazeneca Ab

Invagen Pharmaceuticals Inc

Last Docket Entry Date

Total Docket Entries

United States District of Delaware

1:17-cv-01073 | AstraZeneca LP v. Invagen Pharma Inc | Ex Parte

Name	Ratings
Astrazeneca Pharmaceuticals LP	L5 A
Astrazeneca LP	L5 A
Astrazeneca Uk Ltd	L5 A
Astrazeneca Ab	L5 A

Name	Ratings
Finnegan Henderson Farabow Garrett & Dunner LLP	L5 A
Charles E. Lipsey	L5 A
Mark J. Feldstein	L4 B
Cora R. Holt	L2 A
Jill K. MacAlpine	L1 C
Ryan P. O'Quinn	-- -- --
Maximilienne Giannelli	-- -- --
McCarter & English LLP	L4 A
Michael P. Kelly	L5 A
Daniel M. Silver	L5 A
Benjamin A. Smyth	L3 A

Name	Ratings
Kratz Barry LLP	-- -- --
R. Touhey Myer	-- -- --